PubRank

Marja-Riitta Taskinen

Author PubWeight™ 241.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007 51.70
2 Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008 20.73
3 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 10.52
4 Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010 4.31
5 Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008 4.20
6 Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013 3.58
7 Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011 3.00
8 Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005 2.99
9 Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008 2.96
10 ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 2.90
11 Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004 2.86
12 One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009 2.75
13 Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2008 2.73
14 Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005 2.26
15 [ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol 2011 2.21
16 Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2010 2.03
17 Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet 2012 1.97
18 An immune response network associated with blood lipid levels. PLoS Genet 2010 1.74
19 Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003 1.65
20 Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. Clin Sci (Lond) 2004 1.63
21 Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011 1.53
22 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 1.51
23 Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke 2002 1.50
24 Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005 1.50
25 Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. Am J Hum Genet 2002 1.45
26 Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005 1.44
27 Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy. Atherosclerosis 2011 1.42
28 Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003 1.39
29 PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010 1.34
30 Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002 1.33
31 Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet 2013 1.26
32 Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003 1.26
33 Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 2008 1.26
34 Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Hum Mol Genet 2005 1.25
35 Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genes. PLoS Genet 2010 1.24
36 Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012 1.22
37 Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010 1.21
38 Diabetic dyslipidaemia. Curr Opin Lipidol 2006 1.20
39 Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009 1.19
40 Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. Am J Hum Genet 2003 1.19
41 Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008 1.17
42 APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res 2004 1.16
43 USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet 2005 1.16
44 Common hepatic nuclear factor-4alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes 2006 1.15
45 Statins are diabetogenic--myth or reality? Atheroscler Suppl 2012 1.15
46 Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet 2011 1.13
47 ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009 1.12
48 Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002 1.11
49 A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 2004 1.11
50 Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res 2010 1.10
51 One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010 1.07
52 Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J Clin Endocrinol Metab 2013 1.07
53 Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006 1.07
54 WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am J Hum Genet 2008 1.06
55 OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. J Mol Med (Berl) 2009 1.02
56 Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 2005 1.02
57 Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2009 1.02
58 Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol 2011 1.02
59 Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007 1.02
60 Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity. J Lipid Res 2008 1.01
61 Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease. Am J Cardiol 2006 1.01
62 1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self-organising maps. NMR Biomed 2007 0.98
63 Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab 2009 0.98
64 A genome-wide screen for interactions reveals a new locus on 4p15 modifying the effect of waist-to-hip ratio on total cholesterol. PLoS Genet 2011 0.97
65 Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 2002 0.97
66 Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care 2012 0.95
67 Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis 2010 0.95
68 Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006 0.94
69 Estimation of VLDL, IDL, LDL, HDL2, apoA-I, and apoB from the Friedewald inputs--apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann Med 2009 0.94
70 R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis 2004 0.93
71 Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2013 0.93
72 The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. Atherosclerosis 2006 0.92
73 Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006 0.92
74 Cardiac steatosis and left ventricular function in men with metabolic syndrome. J Cardiovasc Magn Reson 2013 0.92
75 HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res 2008 0.91
76 Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012 0.91
77 Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chem Phys Lipids 2008 0.90
78 A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia. Hum Genet 2009 0.89
79 A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies. Atherosclerosis 2003 0.89
80 Galanin preproprotein is associated with elevated plasma triglycerides. Arterioscler Thromb Vasc Biol 2008 0.88
81 Diabetes as a case study of chronic disease management with a personalized approach: the role of a structured feedback loop. Diabetes Res Clin Pract 2012 0.88
82 Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol 2004 0.88
83 Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL. J Lipid Res 2007 0.87
84 Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res 2004 0.87
85 Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates high-density lipoprotein cholesterol levels. Circ Cardiovasc Genet 2009 0.87
86 Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 2005 0.86
87 Lifestyle modification improves risk factors in type 2 diabetes relatives. Diabetes Res Clin Pract 2005 0.86
88 A candidate gene study in low HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and the APOA1C3A4 gene cluster. Atherosclerosis 2002 0.86
89 Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006 0.86
90 HDL subspecies in young adult twins: heritability and impact of overweight. Obesity (Silver Spring) 2009 0.86
91 Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL. Ann Med 2006 0.85
92 Insulin resistance as predictor of the angiographic severity and extent of coronary artery disease. Ann Med 2007 0.84
93 Characterizing human adipose tissue lipids by long echo time 1H-MRS in vivo at 1.5 Tesla: validation by gas chromatography. NMR Biomed 2010 0.84
94 Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia. J Lipid Res 2004 0.84
95 The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2014 0.83
96 Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality. PLoS One 2007 0.83
97 Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 2002 0.83
98 Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 2007 0.83
99 LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 2002 0.82
100 Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. Atherosclerosis 2010 0.82
101 Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. J Diabetes Complications 2013 0.82
102 Long-TE 1H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. NMR Biomed 2010 0.81
103 Determinants of low HDL levels in familial combined hyperlipidemia. J Lipid Res 2003 0.81
104 Transgenic expression and genetic variation of Lmf1 affect LPL activity in mice and humans. Arterioscler Thromb Vasc Biol 2012 0.81
105 Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance. Mol Biosyst 2012 0.81
106 Dietary omega-3 polyunsaturated fatty acid intake is related to a protective high-density lipoprotein subspecies profile independent of genetic effects: a monozygotic twin pair study. Atherosclerosis 2011 0.81
107 Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care 2002 0.81
108 High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One 2011 0.81
109 A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families. Atherosclerosis 2002 0.81
110 The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity. Diabetes Care 2007 0.81
111 Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J Clin Endocrinol Metab 2015 0.81
112 Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. Eur J Endocrinol 2011 0.80
113 Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles. Bioinformatics 2007 0.80
114 Hypertriglyceridemia is associated with prebeta-HDL concentrations in subjects with familial low HDL. J Lipid Res 2005 0.80
115 Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. Curr Cardiol Rep 2012 0.80
116 Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. Ann Med 2002 0.80
117 Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome. Metabolism 2010 0.79
118 ApoE polymorphism is associated with C-reactive protein in low-HDL family members and in normolipidemic subjects. Mediators Inflamm 2006 0.79
119 C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor gamma expression in adipose tissue of familial combined hyperlipidemia patients. Metabolism 2002 0.79
120 High-fat meals induce systemic cytokine release without evidence of endotoxemia-mediated cytokine production from circulating monocytes or myeloid dendritic cells. Acta Diabetol 2014 0.79
121 The ATF6-Met[67]Val substitution is associated with increased plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2009 0.79
122 Reviewing statin therapy in diabetes--towards the best practise. Prim Care Diabetes 2010 0.79
123 PRESS echo time behavior of triglyceride resonances at 1.5T: detecting omega-3 fatty acids in adipose tissue in vivo. J Magn Reson 2009 0.79
124 Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects. PLoS One 2013 0.79
125 Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. J Clin Endocrinol Metab 2003 0.78
126 Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins. Obesity (Silver Spring) 2014 0.78
127 Should we dismiss fibrates for the treatment of diabetic dyslipidaemia? Nutr Metab Cardiovasc Dis 2006 0.78
128 Correction to the FIELD study report. Lancet 2006 0.78
129 Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia. Atherosclerosis 2002 0.78
130 Optimization of N-methyl-N-[tert-butyldimethylsilyl]trifluoroacetamide as a derivatization agent for determining isotopic enrichment of glycerol in very-low density lipoproteins. Rapid Commun Mass Spectrom 2010 0.78
131 Is metabolic syndrome the main threat to human health in the twenty-first century? Arterioscler Thromb Vasc Biol 2007 0.78
132 Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. J Clin Endocrinol Metab 2014 0.78
133 CVD in women. Nutr Metab Cardiovasc Dis 2010 0.77
134 Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis 2004 0.77
135 Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia. Eur J Hum Genet 2002 0.77
136 Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. Circ Cardiovasc Genet 2009 0.77
137 Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002 0.77
138 Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain. Ann Med 2013 0.77
139 Lipoprotein metabolism in subjects with hepatic lipase deficiency. Metabolism 2004 0.76
140 Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. BMC Endocr Disord 2014 0.76
141 Kinetics of plasma triglycerides in abdominal obesity. Curr Opin Lipidol 2016 0.76
142 ADAGIO-Lipids gives promises but faces the setbacks. Arterioscler Thromb Vasc Biol 2009 0.75
143 A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model. BMC Syst Biol 2013 0.75
144 [New European clinical guidelines on dyslipidemias]. Duodecim 2012 0.75
145 Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2015 0.75
146 Measuring short-term liver metabolism non-invasively: postprandial and post-exercise ¹H and ³¹P MR spectroscopy. MAGMA 2014 0.75
147 [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. Turk Kardiyol Dern Ars 2015 0.75